Published in Leukemia on October 01, 2005
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A (2008) 4.26
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood (2012) 2.65
Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses. Nature (2010) 1.71
FOX(M1) news--it is cancer. Mol Cancer Ther (2013) 1.64
Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma. J Cell Biol (2008) 1.41
miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death. Mol Cancer (2012) 1.21
Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization. Protein Sci (2013) 1.20
Nucleophosmin interacts with FOXM1 and modulates the level and localization of FOXM1 in human cancer cells. J Biol Chem (2011) 1.06
DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML. Genome Biol (2014) 0.95
Targeting AML through DR4 with a novel variant of rhTRAIL. J Cell Mol Med (2011) 0.89
A new DNA-based test for detection of nucleophosmin exon 12 mutations by capillary electrophoresis. J Mol Diagn (2008) 0.87
Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. Blood (2014) 0.87
High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia. Oncotarget (2014) 0.87
Reactivating the ARF-p53 axis in AML cells by targeting ULF. Cell Cycle (2010) 0.86
Hyperforin inhibits Akt1 kinase activity and promotes caspase-mediated apoptosis involving Bad and Noxa activation in human myeloid tumor cells. PLoS One (2011) 0.86
Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing. Mod Pathol (2014) 0.86
Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia? Haematologica (2009) 0.82
Cytoplasmic FANCA-FANCC complex interacts and stabilizes the cytoplasm-dislocalized leukemic nucleophosmin protein (NPMc). J Biol Chem (2010) 0.82
Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy. Int J Nanomedicine (2016) 0.81
Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 Mediate the cellular localization of nucleophosmin and its AML-associated mutants. ACS Chem Biol (2015) 0.80
Prognostic significance of NPM1 mutation-modulated microRNA-mRNA regulation in acute myeloid leukemia. Leukemia (2015) 0.80
The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. Oncotarget (2015) 0.79
Design of FLT3 Inhibitor - Gold Nanoparticle Conjugates as Potential Therapeutic Agents for the Treatment of Acute Myeloid Leukemia. Nanoscale Res Lett (2015) 0.78
Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications. Leukemia (2014) 0.78
Cytoplasmic nucleophosmin has elevated T199 phosphorylation upon which G2/M phase progression is dependent. Sci Rep (2015) 0.78
Oridonin induces NPM mutant protein translocation and apoptosis in NPM1c+ acute myeloid leukemia cells in vitro. Acta Pharmacol Sin (2014) 0.78
Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models. J Hematol Oncol (2016) 0.78
HEXIM1, a New Player in the p53 Pathway. Cancers (Basel) (2013) 0.77
Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients. Curr Pharm Biotechnol (2016) 0.77
Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia. Sci Adv (2016) 0.76
1-Benzyl-2-methyl-3-indolylmethylene barbituric acid derivatives: Anti-cancer agents that target nucleophosmin 1 (NPM1). Bioorg Med Chem (2015) 0.76
The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. Leuk Lymphoma (2014) 0.76
Establishment of a quenching probe method for detection of NPM1 mutations in acute myeloid leukemia cells. Oncol Lett (2016) 0.75
Nuclear FOXM1 drives chemoresistance in AML. Leukemia (2016) 0.75
The human nucleophosmin 1 mutation A inhibits myeloid differentiation of leukemia cells by modulating miR-10b. Oncotarget (2016) 0.75
Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death Dis (2016) 0.75
Down-regulated expression of NPM1 in IMS-M2 cell line by (-)-epigallocatechin-3-gallate. Asian Pac J Trop Biomed (2014) 0.75
An intrabody specific for the nucleophosmin carboxy-terminal mutant and fused to a nuclear localization sequence binds its antigen but fails to relocate it in the nucleus. Biotechnol Rep (Amst) (2014) 0.75
FOXM1 in Cancer: Interactions and Vulnerabilities. Cancer Res (2017) 0.75
Long noncoding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients. Haematologica (2017) 0.75
Active hexose-correlated compound enhances extrinsic-pathway-mediated apoptosis of Acute Myeloid Leukemic cells. PLoS One (2017) 0.75
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood (1994) 21.00
Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem (1984) 18.48
A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell (1992) 6.86
Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med (1998) 5.71
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia (2006) 5.64
Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A (2001) 4.84
Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology (2002) 4.22
CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood (2000) 3.99
Diagnosis of human lymphoma with monoclonal antileukocyte antibodies. N Engl J Med (1983) 3.63
Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood (1999) 3.53
BCL-6 protein is expressed in germinal-center B cells. Blood (1995) 3.18
A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood (2000) 3.13
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet (2004) 2.96
The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell (1993) 2.96
The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene (1995) 2.80
CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood (1995) 2.67
Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med (1997) 2.59
ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol (2000) 2.43
Immunohistological analysis of human mononuclear phagocytes and dendritic cells by using monoclonal antibodies. Lab Invest (1986) 2.42
Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood (1990) 2.40
ALK+ lymphoma: clinico-pathological findings and outcome. Blood (1999) 2.38
Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins. Oncogene (1994) 2.27
Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer (1999) 2.20
False leukemia-lymphoma cell lines: an update on over 500 cell lines. Leukemia (2003) 2.09
Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Blood (1996) 2.02
Antigen retrieval techniques in immunohistochemistry: comparison of different methods. J Pathol (1997) 2.01
A case of TdT-positive B-cell acute lymphoblastic leukemia. Am J Clin Pathol (1986) 1.97
The Pearson product-moment correlation coefficient is better suited for identification of DNA fingerprint profiles than band matching algorithms. Electrophoresis (1993) 1.97
Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol (2001) 1.96
C-kit mutations in core binding factor leukemias. Blood (2000) 1.93
Genistein inhibits tumour cell growth in vitro but enhances mitochondrial reduction of tetrazolium salts: a further pitfall in the use of the MTT assay for evaluating cell growth and survival. Eur J Cancer (1993) 1.92
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia (2006) 1.90
Distribution of T cells bearing different forms of the T cell receptor gamma/delta in normal and pathological human tissues. J Immunol (1989) 1.89
PG-M1: a new monoclonal antibody directed against a fixative-resistant epitope on the macrophage-restricted form of the CD68 molecule. Am J Pathol (1993) 1.81
FLT3 mutations in acute myeloid leukemia cell lines. Leukemia (2003) 1.80
BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood (1989) 1.76
Cloning of human thymic stromal lymphopoietin (TSLP) and signaling mechanisms leading to proliferation. Leukemia (2001) 1.73
Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells? Am J Surg Pathol (2001) 1.68
Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice. J Immunol (1997) 1.68
A revised European-American classification of lymphoid neoplasms proposed by the International Lymphoma Study Group. A summary version. Am J Clin Pathol (1995) 1.67
ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol (1998) 1.64
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. Leukemia (2005) 1.64
ECV304 (endothelial) is really T24 (bladder carcinoma): cell line cross- contamination at source. In Vitro Cell Dev Biol Anim (2000) 1.63
The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer (2003) 1.63
Increased allergen-specific, steroid-sensitive gamma delta T cells in bronchoalveolar lavage fluid from patients with asthma. Ann Intern Med (1996) 1.61
The 5q-anomaly. Cancer Genet Cytogenet (1985) 1.60
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia (2006) 1.60
TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood (1999) 1.59
Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia (2009) 1.56
Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. J Clin Oncol (1996) 1.54
Hodgkin's lymphoma: the pathologist's viewpoint. J Clin Pathol (2002) 1.51
Primary effusion Burkitt's lymphoma with t(8;22) in a patient with hepatitis C virus-related cirrhosis. Hum Pathol (1997) 1.48
Philadelphia chromosome-positive chronic myelogenous leukemia in treated Hodgkin's disease. Cancer Genet Cytogenet (1990) 1.45
Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia (2000) 1.45
Mono Mac 6: a mature monoblastic leukemia cell line with t(9;11)(p21;q23) Blood (1993) 1.43
Does pain confound interpretation of neuropsychological test results? NeuroRehabilitation (2001) 1.41
t(1;19) without detectable E2A rearrangements in two t(14;18)-positive lymphoma/leukemia cases. Genes Chromosomes Cancer (1994) 1.41
Specificity and sensitivity of polymerase chain reaction (PCR) in comparison with other methods for the detection of mycoplasma contamination in cell lines. J Immunol Methods (1993) 1.40
Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study. Blood (1999) 1.40
Incidence of TdT positivity in cases of leukemia and lymphoma. Acta Haematol (1986) 1.38
Variant t(2;18) translocation in a Burkitt conversion of follicular lymphoma. Br J Haematol (1990) 1.38
EZH2 Y641 mutations in follicular lymphoma. Leukemia (2011) 1.37
Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. Leukemia (2007) 1.36
Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood (1999) 1.35
Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia (2009) 1.33
Growth-inhibitory effects of the natural phyto-oestrogen genistein in MCF-7 human breast cancer cells. Eur J Cancer (1994) 1.32
A novel gene, AF-1p, fused to HRX in t(1;11)(p32;q23), is not related to AF-4, AF-9 nor ENL. Oncogene (1994) 1.30
Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains. EMBO J (1996) 1.27
Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. Ann Oncol (1997) 1.26
Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. Gastroenterology (1999) 1.24
Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki-1 + with a high content of reactive histiocytes). Histopathology (1990) 1.24
Detection of mycoplasma in leukemia-lymphoma cell lines using polymerase chain reaction. Leukemia (2002) 1.23
Histological and immunohistological analysis of human lymphomas. Crit Rev Oncol Hematol (1989) 1.22
HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3. Leukemia (2005) 1.21
Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood (1999) 1.20
Detection of normal and chimeric nucleophosmin in human cells. Blood (1999) 1.20